Arix Bioscience participates in US$70mln Harpoon Series C investment round
Including the £6.1mln Series C investment, the value of Arix’s 11.3% stake in Harpoon has increased to £20.2mln
Company
Arix Bioscience PLC
LON:ARIX
Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. The company collaborates with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.
180 stories · page 7 of 9
Archive
Proactive news snapshot: Mporium Group, Goldplat, Bluebird Merchant Ventures …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial
The data from a phase Ib/II trial of Aura’s AU-011 eye cancer treatment show the injection doesn’t do too much damage to the surrounding healthy tissue in patients’ eyes
Archive
Proactive news snapshot: WideCells Group. Sunrise Resources, SIMEC Atlantis Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Ethernity Networks, Landore Resources, Capital Drilling …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences boost after investee company floats on NASDAQ
The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio
Essentra dips after mixed trading update, Dechra Pharma trots up on acquisition news
A look at some winners and losers in UK equity trading during Friday's session
Archive
Proactive news snapshot: Hemogenyx Pharmaceuticals, PhotonStar LED, Futura Medical …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq
As a result of the IPO, the value of Arix’s stake in LogicBio has soared to almost £23mln, including the extra investment announced today
FTSE 100 closes ahead as US earnings season gets off to strong start
The UK blue-chip index closed up almost 23 points at 7,049 - up around 0.77% on the week as a whole
Archive
Proactive news snapshot: Advanced Oncotherapy, Alba Mineral Resources, Wolf Minerals...
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience’s stake in LogicBio to soar in value once gene editing biotech floats in New York
Arix reckons the value of its stake will more than triple, but it isn’t cashing in just yet, instead it wants to buy up more shares at the IPO
Investments and investor services
Arix Biosciences forges partnership with Fred Hutch and Evotech to invest and create new drug companies focused on oncology
The partnership creates LAB591 as an academic bridge to cut down the time it takes for drug research programs to move from the lab to the market
Archive
Proactive news snapshot: Greatland Gold, European Metals, Chesnara, BigDish...
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience teams up with Takeda to invest in cancer drug developer VelosBio
Arix is investing US$11mln in VelosBio through a Series A funding round in return for an 11.2% stake in the company
FTSE 100 closes in red; Royal Mail delivers share plunge
The UK blue-chip index closed down around 14 points at 7,495 as the stronger pound weighed
Archive
Proactive news snapshot: Amryt Pharma, Directa Plus, Live Company...
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences investee company eyeing NASDAQ float
LogicBio is a specialist in genome editing that is developing drugs for rare diseases
Investments and investor services
FTSE 100 closes near flat as traders sit on hands ahead of Fed
The UK blue-chip index closed nearly four points higher at 7,511
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target